Literature DB >> 35481304

Adverse Reaction to COVID-19 mRNA Vaccination in a Patient With VEXAS Syndrome.

Giulio Ciprian1.   

Abstract

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a rare genetic disorder originating from a somatic mutation in the hematopoietic stem cells. This syndrome was first described in 2020 and carries many clinical features that other conditions cannot explain. Widespread autoinflammation is the primary process the disease presents, with high morbidity and mortality in those who show signs of bone marrow failure. Treatment is complex, and response to current therapies is poor. Long-term prognosis carries a mortality of 50%. In addition, the advancement of new-generation messenger ribonucleic acid (mRNA) vaccines raises concerns about their safety in this population since it could trigger a vaccine-related autoimmune response. This case describes the hospital course of a male in his 50s exhibiting an unexplained cutaneous reaction to an mRNA COVID-19 vaccine. He was later diagnosed with VEXAS syndrome based on symptoms presentation and diagnostic workup.
Copyright © 2022, Ciprian et al.

Entities:  

Keywords:  acute rheumatology; covid-19; multiple autoimmune syndrome; uba1; vexas

Year:  2022        PMID: 35481304      PMCID: PMC9034849          DOI: 10.7759/cureus.23456

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  17 in total

1.  Tocilizumab for the treatment of adult-onset Still's disease.

Authors:  Santos Castañeda; Dolores Martínez-Quintanilla; José L Martín-Varillas; Noelia García-Castañeda; Belén Atienza-Mateo; Miguel A González-Gay
Journal:  Expert Opin Biol Ther       Date:  2019-04       Impact factor: 4.388

2.  Toward a pathophysiology inspired treatment of VEXAS syndrome.

Authors:  Maël Heiblig; Bhavisha A Patel; Emma M Groarke; Estelle Bourbon; Pierre Sujobert
Journal:  Semin Hematol       Date:  2021-10-05       Impact factor: 3.851

3.  Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL-6.

Authors:  Qian Zhang; Kai Zhao; Qicong Shen; Yanmei Han; Yan Gu; Xia Li; Dezhi Zhao; Yiqi Liu; Chunmei Wang; Xiang Zhang; Xiaoping Su; Juan Liu; Wei Ge; Ross L Levine; Nan Li; Xuetao Cao
Journal:  Nature       Date:  2015-08-19       Impact factor: 49.962

Review 4.  Therapeutic options in VEXAS syndrome: insights from a retrospective series.

Authors:  Estelle Bourbon; Maël Heiblig; Mathieu Gerfaud Valentin; Thomas Barba; Cécile-Audrey Durel; Jean Christophe Lega; Fiorenza Barraco; Pascal Sève; Yvan Jamilloux; Pierre Sujobert
Journal:  Blood       Date:  2021-07-01       Impact factor: 22.113

5.  Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS.

Authors:  Caspar I van der Made; Judith Potjewijd; Annemiek Hoogstins; Huub P J Willems; Arjan J Kwakernaak; Ruud G L de Sevaux; Paul L A van Daele; Annet Simons; Marloes Heijstek; David B Beck; Mihai G Netea; Pieter van Paassen; A Elizabeth Hak; Lars T van der Veken; Marielle E van Gijn; Alexander Hoischen; Frank L van de Veerdonk; Helen L Leavis; Abraham Rutgers
Journal:  J Allergy Clin Immunol       Date:  2021-05-25       Impact factor: 10.793

6.  Case Report: Genetic Double Strike: VEXAS and TET2-Positive Myelodysplastic Syndrome in a Patient With Long-Standing Refractory Autoinflammatory Disease.

Authors:  Fabian Lötscher; Luca Seitz; Helena Simeunovic; Adela-Cristina Sarbu; Naomi A Porret; Laurence Feldmeyer; Luca Borradori; Nicolas Bonadies; Britta Maurer
Journal:  Front Immunol       Date:  2022-01-20       Impact factor: 7.561

7.  Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience.

Authors:  Ava Diarra; Nicolas Duployez; Elise Fournier; Claude Preudhomme; Valérie Coiteux; Leonardo Magro; Bruno Quesnel; Maël Heiblig; Pierre Sujobert; Fiorenza Barraco; Marie Balsat; Quentin Scanvion; Eric Hachulla; David Launay; Ibrahim Yakoub-Agha; Louis Terriou
Journal:  Blood Adv       Date:  2022-02-08

8.  Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease.

Authors:  David B Beck; Marcela A Ferrada; Keith A Sikora; Amanda K Ombrello; Jason C Collins; Wuhong Pei; Nicholas Balanda; Daron L Ross; Daniela Ospina Cardona; Zhijie Wu; Bhavisha Patel; Kalpana Manthiram; Emma M Groarke; Fernanda Gutierrez-Rodrigues; Patrycja Hoffmann; Sofia Rosenzweig; Shuichiro Nakabo; Laura W Dillon; Christopher S Hourigan; Wanxia L Tsai; Sarthak Gupta; Carmelo Carmona-Rivera; Anthony J Asmar; Lisha Xu; Hirotsugu Oda; Wendy Goodspeed; Karyl S Barron; Michele Nehrebecky; Anne Jones; Ryan S Laird; Natalie Deuitch; Dorota Rowczenio; Emily Rominger; Kristina V Wells; Chyi-Chia R Lee; Weixin Wang; Megan Trick; James Mullikin; Gustaf Wigerblad; Stephen Brooks; Stefania Dell'Orso; Zuoming Deng; Jae J Chae; Alina Dulau-Florea; May C V Malicdan; Danica Novacic; Robert A Colbert; Mariana J Kaplan; Massimo Gadina; Sinisa Savic; Helen J Lachmann; Mones Abu-Asab; Benjamin D Solomon; Kyle Retterer; William A Gahl; Shawn M Burgess; Ivona Aksentijevich; Neal S Young; Katherine R Calvo; Achim Werner; Daniel L Kastner; Peter C Grayson
Journal:  N Engl J Med       Date:  2020-10-27       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.